Skip to main content

Table 3 The pCR rates according to the pathological subtypes

From: Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Pathologic subtype

Pathological response

CR (n = 16)

Non-CR (n = 39)

HR+, HER-2− (n = 31)

8 (25%)

23 (75%)

HR+, HER-2+ (n = 9)

2 (22%)

7 (78%)

HR−, HER-2 + (n = 7)

3 (42%)

4 (58%)

HR−, HER-2− (n = 8)

3 (38%)

5 (62%)

  1. HR hormon receptor, Her-2 human epidermal growth factor receptor 2